Your browser doesn't support javascript.
loading
Characterization of Ebola Virus-Associated Eye Disease.
Eghrari, Allen O; Bishop, Rachel J; Ross, Robin D; Davis, Bionca; Larbelee, Jemma; Amegashie, Fred; Dolo, Robert F; Prakalapakorn, S Grace; Gaisie, Catherine; Gargu, Catherine; Sosu, Yassah; Sackor, Jennie; Cooper, Precious Z; Wallace, Augustine; Nyain, Ruth; Gray, Maima; Kamara, Famatta; Burkholder, Bryn; Brady, Christopher J; Ray, Vincent; Tawse, Kirstin L; Yeung, Ian; Neaton, James D; Higgs, Elizabeth S; Lane, H Clifford; Reilly, Cavan; Sneller, Michael C; Fallah, Mosoka P.
Afiliação
  • Eghrari AO; Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland.
  • Bishop RJ; National Institutes of Health, Bethesda, Maryland.
  • Ross RD; Global Retina Institute, Scottsdale, Arizona.
  • Davis B; Division of Biostatistics, University of Minnesota, Minneapolis.
  • Larbelee J; Redemption Hospital, Monrovia, Liberia.
  • Amegashie F; Liberian Ministry of Health, Monrovia, Liberia.
  • Dolo RF; New Sight Eye Centre, Paynesville, Liberia.
  • Prakalapakorn SG; Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina.
  • Gaisie C; New Sight Eye Centre, Paynesville, Liberia.
  • Gargu C; Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.
  • Sosu Y; Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.
  • Sackor J; Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.
  • Cooper PZ; Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.
  • Wallace A; Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.
  • Nyain R; Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.
  • Gray M; Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.
  • Kamara F; Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.
  • Burkholder B; Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland.
  • Brady CJ; University of Vermont School of Medicine, Burlington.
  • Ray V; Department of Ophthalmology, California Pacific Medical Center, San Francisco.
  • Tawse KL; Department of Ophthalmology, Kaiser Permanente, Denver, Colorado.
  • Yeung I; National Institutes of Health, Bethesda, Maryland.
  • Neaton JD; Division of Biostatistics, University of Minnesota, Minneapolis.
  • Higgs ES; National Institutes of Health, Bethesda, Maryland.
  • Lane HC; National Institutes of Health, Bethesda, Maryland.
  • Reilly C; Division of Biostatistics, University of Minnesota, Minneapolis.
  • Sneller MC; National Institutes of Health, Bethesda, Maryland.
  • Fallah MP; National Public Health Institute of Liberia, Monrovia, Liberia.
JAMA Netw Open ; 4(1): e2032216, 2021 01 04.
Article em En | MEDLINE | ID: mdl-33399856
ABSTRACT
Importance Survivors of Ebola virus disease (EVD) may experience ocular sequelae. Comparison with antibody-negative individuals from the local population is required to characterize the disease.

Objective:

To assess features of ophthalmic disease specific to EVD. Design, Setting, and

Participants:

This baseline cross-sectional analysis of survivors of EVD and their close contacts was conducted within PREVAIL III, a 5-year, longitudinal cohort study. Participants who enrolled at John F. Kennedy Medical Center in Liberia, West Africa from June 2015 to March 2016 were included in this analysis. Close contacts were defined as household members or sex partners of survivors of EVD. Data were analyzed from July 2016 to July 2020. Exposures All participants, both survivors and close contacts, underwent testing of IgG antibody levels against Ebola virus surface glycoprotein. Main Outcomes and

Measures:

Ocular symptoms, anterior and posterior ophthalmologic examination findings, and optical coherence tomography images were compared between antibody-positive survivors and antibody-negative close contacts.

Results:

A total of 564 antibody-positive survivors (320 [56.7%] female; mean [SD] age, 30.3 [14.0] years) and 635 antibody-negative close contacts (347 [54.6%] female; mean [SD] age, 25.8 [15.5] years) were enrolled in this study. Survivors were more likely to demonstrate color vision deficit (28.9% vs 19.0%, odds ratio [OR], 1.6; 95% CI, 1.2-2.1) and lower intraocular pressure (12.4 vs 13.5 mm Hg; mean difference, -1.2 mm Hg; 95% CI, -1.6 to -0.8 mm Hg) compared with close contacts. Dilated fundus examination revealed a higher percentage of vitreous cells (7.8% vs 0.5%; OR, 16.6; 95% CI, 5.0-55.2) and macular scars (4.6% vs 1.6%; OR, 2.8; 95% CI, 1.4-5.5) in survivors than in close contacts. Uveitis was present in 26.4% of survivors and 12.1% of close contacts (OR, 2.4; 95% CI, 1.8-3.2). Among all participants with uveitis, survivors were more likely than close contacts to have intermediate uveitis (34.2% vs 6.5% of all cases; OR, 7.8; 95% CI, 3.1-19.7) and had thicker mean central subfield thickness on optical coherence tomography (222 vs 212 µm; mean difference, 14.4 µm; 95% CI, 1.9-26.9 µm). Conclusions and Relevance In this cross-sectional study, survivors of EVD had a distinct spectrum of ocular and neuro-ophthalmologic findings compared with close contacts that potentially require medical and surgical treatment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sobreviventes / Doença pelo Vírus Ebola / Oftalmopatias Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: JAMA Netw Open Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sobreviventes / Doença pelo Vírus Ebola / Oftalmopatias Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: JAMA Netw Open Ano de publicação: 2021 Tipo de documento: Article